21392-48-3

Usage

Uses

Used in Pharmaceutical Industry:
7-HYDROXY-8-METHYL-4-PHENYL-2H-CHROMEN-2-ONE is used as a potential therapeutic agent for oxidative stress-related diseases due to its antioxidant properties. It can help mitigate the effects of oxidative stress, which is implicated in the pathogenesis of numerous conditions.
Used in Anti-inflammatory Applications:
In the field of inflammation, 7-HYDROXY-8-METHYL-4-PHENYL-2H-CHROMEN-2-ONE is used as an anti-inflammatory agent, leveraging its ability to reduce inflammation which is a common factor in many chronic diseases.
Used in Oncology:
7-HYDROXY-8-METHYL-4-PHENYL-2H-CHROMEN-2-ONE is used as an anti-cancer agent, showing promise in the development of novel therapeutics for various types of cancer due to its ability to target and inhibit cancer cell growth and proliferation.
Used in Neurological Research:
7-HYDROXY-8-METHYL-4-PHENYL-2H-CHROMEN-2-ONE is used as a neuroprotective agent in neurology, with potential applications in the treatment and management of neurodegenerative diseases, given its capacity to protect neurons from damage and degeneration.

InChI:InChI=1/C16H12O3/c1-10-14(17)8-7-12-13(9-15(18)19-16(10)12)11-5-3-2-4-6-11/h2-9,17H,1H3

Upstream product

• 94-02-0 ethyl 3-oxo-3-phenylpropionate 
• 87-66-1 2-hydroxyresorcinol 
• 608-25-3 2-methylbenzene-1,3-diol 
• 2216-94-6 phenylpropynoic acid ethyl ester 
• 93-89-0 benzoic acid ethyl ester 
• 65-85-0 benzoic acid 

Downstream Products

• 314742-99-9 8-methyl-7-(1-methyl-2-oxo-2-phenylethoxy)-4-phenylcoumarin 
• 1000007-00-0 3-bromo-7-hydroxy-8-methyl-4-phenyl-2H-chromen-2-one 
• 1352006-38-2 dibenzyl 8-methyl-2-oxo-4-phenyl-2H-chromen-7-yl phosphate 
• 1352006-45-1 8-methyl-2-oxo-4-phenyl-2H-chromene-7-yl dihydrogen phosphate 

Relevant academic research and scientific papers

Synthesis of Novel Anti-inflammatory Psoralen Derivatives?-?Structures?with?Distinct?Anti-Inflammatory?Activities

As a continuum to our work with coumarins, 12 psoralens were synthesized and evaluated for their anti-inflammatory activity. Psoralens were prepared in three steps; at first, 7-hydroxycoumarins were synthesized by von Pechmann condensation and then converted to 7-(2-oxopropoxy)coumarins. In the final step, a fused furan ring was introduced in an intramolecular ring-formation reaction. Based on a SciFinder search, two out of the 12 synthesized psoralen derivatives (compounds 9 and 12) were found to be novel. The derivatives displayed anti-inflammatory activity by suppressing iNOS and IL-6 expression, but their mechanism of action seemed to be dependent on the substitution. Compound 6 with propyl side chain inhibited NF-κB mediated transcription, while compound 10 with a phenyl substituent down-regulated iNOS expression in a posttranscriptional manner. The results introduce psoralen derivatives as promising anti-inflammatory compounds with potential for treatment of conditions involving iNOS and/or IL-6-mediated adverse responses.

Inhibitory effects and structural insights for a novel series of coumarin-based compounds that selectively target human CA IX and CA XII carbonic anhydrases

Coumarin derivatives are a peculiar class of inhibitors of the family of metalloenzymes carbonic anhydrases (CA, EC 4.2.1.1). Several coumarins display higher affinity and selectivity toward most relevant and druggable CA isoforms. By decorating the natur

SnCl4 grafted on silica gel: an efficient catalyst for solvent-free synthesis of coumarins via the Pechmann condensation

A facile synthesis of substituted coumarins via Pechmann condensation catalyzed by SnCl4 grafted on silica gel is described, which was conducted under solvent-free condition in high yields. The catalyst is noncorrosive and can be easily prepared and separated from the reaction mixture. This methodology offers some advantages with regard to yield of products, simplicity in operation and green aspects.

Preparation of a novel, efficient, and recyclable magnetic catalyst, γ-Fe2O3@HAp-Ag nanoparticles, and a solvent- and halogen-free protocol for the synthesis of coumarin derivatives

In this protocol, Ag supported on the hydroxyapatite-core–shell magnetic γ-Fe2O3nanoparticles (γ-Fe2O3@HAp-Ag NPs) as a novel, efficient, and magnetically recyclable catalyst is synthesized, and characterized by transmission electron microscopy (TEM), scanning electron microscopy (SEM), Fourier transform infrared spectroscopy (FT-IR), X-ray diffraction (XRD), and vibrating sample magnetometry (VSM). The use of the catalyst is described in the synthesis of coumarin derivatives by the Pechmann condensation of various phenols with β-ketoesters under solvent- and halogen-free conditions at 80?°C. This novel and inexpensive method offers advantages, such as recyclability simple experimental protocol, short reaction time, minimal work-up procedure, and excellent yields of products, together with desirable, eco-friendly, green aspects by avoiding toxic elements and solvents, and ease of recovery from the reaction mixture using an external magnet.

7-substituted-4-aryl coumarins compound, and preparation method and application thereof

The invention discloses a 7-substituted-4-aryl coumarins compound, and a preparation method and an application thereof and belongs to the technical field of antitumor drugs. The 7-substituted-4-aryl coumarins compound is acquired in the manner of modifying and remolding 4 and 7 loci of the coumarins. The structural formula is shown in the specification. A pharmacological experiment proves that such a compound has an excellent antitumor activity, can be used for preparing the antitumor drugs, is capable of supplying a new selection for the development and application of the antitumor drugs and further can be applied to the design and optimization of the antitumor drugs. The preparation method of the compound has the advantages of easily acquired raw materials, mild reaction condition, easily realized synthesis method, simple reaction process and operation, low-cost reagents and higher yield.

Rational Design, Synthesis and Evaluation of Coumarin Derivatives as Protein-protein Interaction Inhibitors

Herein we describe the design and synthesis of a new series of coumarin derivatives searching for novel HIV-1 integrase (IN) allosteric inhibitors. All new obtained compounds were tested in order to evaluate their ability to inhibit the interaction between the HIV-1 IN enzyme and the nuclear protein lens epithelium growth factor LEDGF/p75. A combined approach of docking and molecular dynamic simulations has been applied to clarify the activity of the new compounds. Specifically, the binding free energies by using the method of molecular mechanics-generalized Born surface area (MM-GBSA) was calculated, whereas hydrogen bond occupancies were monitored throughout simulations methods.

KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION

The present invention relates to a compound of the general formula (III) or a salt, solvate or prodrug thereof, as well as medical uses involving them, wherein (III) A1 is selected from the group consisting of N and C-R8; A2 is selected from the group consisting of N and C-R3; A3 is selected from the group consisting of N and C-R9; A4 and A5 and A6 are independently selected from the group consisting of N and C-R1; R1 is selected from the group consisting of hydrogen, (C1-C3)alkyl, halogen, (C1-C3)alkoxy and (C1-C3)haloalkyl; R2 is selected from the group consisting of hydrogen, halogen and (C1-C3)alkyl; R3 is selected from the group consisting of hydrogen, (C1-C3)alkyl, NR4R5, (C1-C3)alkyl- NR4R5 and cyano; wherein R4 and R5 are independently selected from the group consisting of hydrogen, (C3- C5)cycloalkyl, (C3-C5)heterocycloalkyl, (C1-C3)alkyl, or R4 and R5 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally comprising in addition to the aforementioned nitrogen atom a further heteroatom group selected from the group consisting of O and NR6, wherein R6 is selected from the group consisting of hydrogen, methyl, acetyl and formyl; Y is selected from the group consisting of O and S; R7 is selected from the group consisting of hydrogen, and (C1-C3)alkyl; R8 is selected from the group consisting of (C1-C4)alkyl, (C3-C5)cycloalkyl, and (C3- C5)heterocycloalkyl; R9 is selected from the group consisting of hydrogen, (C1-C3)alkyl, (C1-C3)alkoxy, and methods for producing such compounds.

KV1.3 INHIBITORS AND THEIR MEDICAL APPLICATION

The present invention relates to a compound of the general formula (II) or a salt or solvate thereof, as well as medical uses involving them, wherein A1 is selected from the group consisting of N and C-R8; A2 is selected from the group consisting of N and C-R3, A3 is selected from the group consisting of N and C-R9; A4 and A5 and A6 are independently selected from the group consisting of N and C-R1; R1 is selected from the group consisting of hydrogen, (C1-C3)alkyl, halogen, (C1-C3)alkoxy, and (C1-C3)haloalkyl; R2 is selected from the group consisting of hydrogen, halogen, and (C1-C3)alkyl; R3 is selected from the group consisting of hydrogen, (C1-C3)alkyl, NR4R5, (C1-C3)alkyl- NR4R5, and cyano, wherein R4 and R5 are independently selected from the group consisting of hydrogen, (C3-C5)cycloalkyl, (C3-C5)heterocycloalkyl and (C1-C3)alkyl, or R4 and R5 together with the nitrogen atom to which they are attached form a 5- to 7-membered heterocyclic ring optionally comprising in addition to the aforementioned nitrogen atom a further heteroatom group selected from the group consisting of O and NR6, wherein R6 is selected from the group consisting of hydrogen, methyl, acetyl and formyl; Y is selected from the group consisting of O and S; R8 is selected from the group consisting of (C1-C4)alkyl, (C3-C5)cycloalkyl and (C3-C5)heterocycloalkyl; and R9 is selected from the group consisting of hydrogen, (C1-C3)alkyl and (C1-C3)alkoxy; wherein certain particular compounds are excluded py proviso, and methods for producing such compounds.

Synthesis and anti-inflammatory effects of a series of novel 7-hydroxycoumarin derivatives

A number of 7-hydroxycoumarins have been synthesised by Pechmann cyclisation using differently substituted resorcinols employing perchloric acid as the condensing agent. All the compounds have been characterised by analytical and spectroscopic methods. The anti-inflammatory properties were tested with LPS-induced inflammation in J774 macrophages. Expression of iNOS and COX-2 was determined by Western blot, NO by nitrite assay and IL-6 by ELISA analyses. Fifteen of the tested 7-hydroxycoumarins also inhibited IL-6 production but none of them had any major inhibitory effect on COX-2 expression.

Synthesis and α-glucosidase inhibitory, DPPH scavenging activity of substituted 2-oxo-2H-chromen-7-yl-dihydrogen phosphate derivatives

Series of phosphorylated coumarin derivatives (4a-j) were synthesized by Pechmann condensation, phosphorylation, and debenzylation reactions in very good yields. Thus, synthesized compounds (4a-j) were evaluated for their α-glucosidase and 1,1-diphenyl-2-picrylhydrazyl scavenging activities; few compounds showed moderate to good activity. J. Heterocyclic Chem., 00, 00 (2011). Copyright